Intranasal flunisolide treatment in patients with non-allergic rhinitis

Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):401-9. doi: 10.1177/039463201102400213.

Abstract

Non-allergic rhinitis (NAR) is a heterogeneous disease, characterized by nasal hyperreactivity and inflammation. Its treatment is still debated, intranasal corticosteroids may be an option. The present study is aimed at evaluating the effect of the use of intranasal flunisolide in patients with NAR, considering both clinical and cytological parameters. Sixty patients were treated with intranasal flunisolide (30) or saline solution (30) for 8 weeks. Symptom severity, turbinate size, and inflammatory cell counts were assessed, before and after treatment. Intranasal flunisolide induced a significant reduction of symptoms, turbinate size, and cellular infiltrate. Thus, intranasal flunisolide might be a therapeutic option for NAR.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Inhalation
  • Adult
  • Anti-Inflammatory Agents / administration & dosage*
  • Female
  • Fluocinolone Acetonide / administration & dosage
  • Fluocinolone Acetonide / analogs & derivatives*
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Nebulizers and Vaporizers
  • Rhinitis / diagnosis
  • Rhinitis / drug therapy*
  • Rhinitis / immunology
  • Severity of Illness Index
  • Single-Blind Method
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Inflammatory Agents
  • Fluocinolone Acetonide
  • flunisolide